{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:57:07Z","timestamp":1792270627725,"version":"4.4.0"},"reference-count":26,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2024,6,8]],"date-time":"2024-06-08T00:00:00Z","timestamp":1717804800000},"content-version":"vor","delay-in-days":159,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clin &amp; Trans Imm"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>This <jats:italic>post hoc<\/jats:italic> analysis assessed disease characteristics and response to dupilumab treatment in male and female patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP) (SINUS\u201052 study; NCT02898454).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients received dupilumab 300\u2009mg or placebo every 2\u2009weeks for 52\u2009weeks on background intranasal corticosteroids. Efficacy was assessed through Week 52 using nasal polyp score (NPS), nasal congestion\/obstruction score, loss of smell score and University of Pennsylvania Smell Identification Test score. Disease\u2010specific health\u2010related quality of life (HRQoL) was assessed using the 22\u2010item Sino\u2010Nasal Outcome Test (SNOT\u201022).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The analysis included 192 male and 111 female patients. Female patients had higher mean SNOT\u201022 total score (56.6 vs. 49.1, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.01) and more\u00a0coexisting asthma (78.4% vs. 46.4%, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.0001) and non\u2010steroidal anti\u2010inflammatory drug\u2010exacerbated respiratory disease (NSAID\u2010ERD) (38.7% vs. 18.8%, <jats:italic>P<\/jats:italic>\u2009=\u20090.0001) than male patients, but other baseline characteristics were similar. Dupilumab significantly improved CRSwNP outcomes vs. placebo at Week 52, regardless of gender: least squares mean differences (95% confidence interval) for NPS were \u22122.33 (\u22122.80, \u22121.86) in male and \u22122.54 (\u22123.18, \u22121.90) in female patients (both <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.0001 vs. placebo), and for SNOT\u201022 were \u221219.2 (\u221224.1, \u221214.2) in male and \u221224.4 (\u221231.5, \u221217.3) in female patients (both <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.0001 vs. placebo). There were no significant efficacy\u2010by\u2010gender interactions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Female patients had greater asthma, NSAID\u2010ERD and HRQoL burden at baseline than male patients. Dupilumab treatment significantly improved objective and subjective outcomes compared with placebo, irrespective of gender.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cti2.1511","type":"journal-article","created":{"date-parts":[[2024,6,8]],"date-time":"2024-06-08T11:58:04Z","timestamp":1717847884000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Dupilumab improves outcomes in patients with chronic rhinosinusitis with nasal polyps irrespective of gender: results from the <scp>SINUS<\/scp>\u201052 trial"],"prefix":"10.1002","volume":"13","author":[{"given":"Wytske J","family":"Fokkens","sequence":"first","affiliation":[{"name":"Department of Otorhinolaryngology Amsterdam University Medical Centres  Amsterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Bachert","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology \u2013 Head and Neck Surgery University Hospital of M\u00fcnster  M\u00fcnster Germany"},{"name":"International Airway Research Center First Affiliated Hospital, Sun Yat\u2010sen University  Guangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Hopkins","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology King's College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osama","family":"Marglani","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Otolaryngology \u2013 Head and Neck Surgery Umm Al\u2010Qura University  Makkah Saudi Arabia"},{"name":"King Faisal Specialist Hospital and Research Center  Jeddah Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Praestgaard","sequence":"additional","affiliation":[{"name":"Department of Biostatistics Sanofi  Cambridge MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Nash","sequence":"additional","affiliation":[{"name":"Medical Affairs Regeneron Pharmaceuticals Inc.  Tarrytown NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yamo","family":"Deniz","sequence":"additional","affiliation":[{"name":"Medical Affairs Regeneron Pharmaceuticals Inc.  Tarrytown NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J","family":"Rowe","sequence":"additional","affiliation":[{"name":"Global Medical Affairs Sanofi  Bridgewater NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry","family":"Sacks","sequence":"additional","affiliation":[{"name":"Medical Affairs Regeneron Pharmaceuticals Inc.  Tarrytown NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juby A","family":"Jacob\u2010Nara","sequence":"additional","affiliation":[{"name":"Global Medical Affairs Sanofi  Bridgewater NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,6,8]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2017.1298443"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2019.05.009"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/alr.23249"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.2147\/JAA.S290424"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anorl.2017.05.005"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.2500\/ajra.2016.30.4297"},{"key":"e_1_2_9_8_1","first-page":"343","article-title":"The GALEN rhinosinusitis cohort: chronic rhinosinusitis with nasal polyps affects health\u2010related quality of life","volume":"57","author":"Khan A","year":"2019","journal-title":"Rhinology"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2019.7194"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-30726-3_1"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0022215107001302"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.2500\/ar.2015.6.0120"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/alr.21667"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/iid3.46"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1177\/01945998221076468"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.14151"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31881-1"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00405-020-06418-5"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2020.09.063"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.01.024"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyg.2019.00242"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2021.01.012"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.15067"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.2500\/aap.2023.44.230015"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/alr.22780"},{"key":"e_1_2_9_26_1","first-page":"301","article-title":"Dupilumab reduces systemic corticosteroid use and sinonasal surgery rate in CRSwNP","volume":"59","author":"Desrosiers M","year":"2021","journal-title":"Rhinology"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/lary.29766"}],"container-title":["Clinical &amp; Translational Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cti2.1511","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T08:49:06Z","timestamp":1719305346000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cti2.1511"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["10.1002\/cti2.1511"],"URL":"https:\/\/doi.org\/10.1002\/cti2.1511","archive":["Portico"],"relation":{},"ISSN":["2050-0068","2050-0068"],"issn-type":[{"value":"2050-0068","type":"print"},{"value":"2050-0068","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"2023-12-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-25","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-08","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e1511"}}